Zeno Health Obtains $25 Million in Series C investment

Zeno Health has successfully raised $25 million in Series C funding, led by Korean PE firm STIC Investments and supported by existing investor Lightbox. This funding will help Zeno Health expand its consumer reach, enlarge its footprint, and enhance its technology infrastructure. Zeno Health, known for its omnichannel pharmacy platform in India, aims to provide quality and affordable generic medicines by streamlining the traditional supply chain.

The following article originally appeared in Express Pharma.

Zeno Health, an omnichannel platform for generic medicines, announced the successful closure of its Series C funding round, securing a total of $5 million. The round has been led by Korean private equity investor STIC Investments. Existing Zeno Health investor Lightbox was also a significant participant in the round.

The company informed that the $25 million capital injection will be pivotal in propelling Zeno Health’s initiatives to reach more consumers, expand its footprint, and further enhance its technological infrastructure.

STIC, the leading Korean investor at the forefront of transformative investments, expressed enthusiasm about the partnership.

“Zeno Health has demonstrated a remarkable commitment to reshaping the healthcare landscape in India. Their vision aligns with our values, and we look forward to contributing to their journey towards making quality healthcare accessible across India,” said Derrick (Kihyun) Yun, MD, STIC.

“In the five years since we invested in Zeno, the company has created the country’s largest omnichannel pharmacy platform for quality and affordable generic medicines. It has been able to do that by disintermediating the traditional supply chain and going directly from the manufacturer to the consumer, thereby building a high gross margin business that is now poised for accelerated growth,” said Sandeep Murthy – Founder and Managing Director, Lightbox.

For more, please find the original story source here.